More Articles

EU problematic patent settlements remain at low level Reports | Posted 17/01/2014

The European Commission’s (EC) fourth monitoring exercise of patent settlements in the pharmaceutical sector has shown the number of potentially problematic settlements under EU antitrust rules rem...

Topics presented at the 16th IGPA conference on generics Conferences | Posted 17/01/2014

Topics presented at the 16th Annual IGPA Conference, held in Brussels, Belgium, 9–11 December 2013, showed that despite differences in the pharmaceutical market in different countries most apprecia...

Biogen and Samsung make deal for marketing anti-TNF biosimilars Biosimilars/News | Posted 17/01/2014

US biotechnology company Biogen Idec (Biogen) and Korean electronics giant Samsung announced on 17 December 2013 that Biogen has exercised its right to enter into an agreement to commercialize anti...

ANI Pharmaceuticals acquires 31 generics from Teva Generics/News | Posted 17/01/2014

US-based brand-name and generics manufacturer ANI Pharmaceuticals (ANI) announced on 26 December 2013 that it had acquired 31 previously marketed generic drugs from Teva Pharmaceutical Industries (...

Biosimilars applications under review by EMA – 2013 Q4 Biosimilars/General | Posted 17/01/2014

Last update: 17 January 2014The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars...

EMA and FDA launch joint generics inspections Policies & Legislation | Posted 17/01/2014

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will work together to ensure the safety of generic medicines. It is hoped that streamlining the inspection process...

Pricing dispute causing drug shortages in Pakistan Pharma News | Posted 17/01/2014

Pharmaceutical manufacturers in Pakistan are warning the Pakistan Government that shortages in life-saving drugs are a result of the ongoing dispute over drug prices.

J&J adds its opinion to biosimilars naming debate Biosimilars/General | Posted 10/01/2014

In the ongoing saga over how to name biosimilars healthcare giant Johnson & Johnson (J&J) has added its opinion to the melting pot; petitioning the US Food and Drug Administration (FDA) to...